Menu
Innovation Observatory > Reports > Mental Health, Drug Abuse and Learning Difficulties

Results

Drugs

December 2017

Esketamine for Treatment-resistant Depression

Currently there are no approved treatments for patients with depression who are at an imminent risk for suicide. Esketamine is currently in development as a spray through the nose (intranasal) for the treatment of treatment-resistant depression in adults.

Drugs

May 2017

Lumateperone for acute exacerbations of psychosis in schizophrenia

Lumateperone is a new, orally administered antipsychotic drug which alters levels of several chemicals in the brain including dopamine, serotonin and glutamate. Studies on lumateperone in people with schizophrenia experiencing an episode of severe symptoms suggest it may reduce symptoms with less side effects than current antipsychotic medication.If licensed lumateperone may provide an alternative treatment …

Devices

March 2017

Monarch™ External Trigeminal Nerve Stimulation (eTNS) System for attention deficit hyperactive disorder (ADHD)

The Monarch™ external trigeminal nerve stimulation system (eTNS system) is a non-invasive device to treat attention deficit hyperactive disorder (ADHD) in children, young people and adults aged seven years and above. People with ADHD have behavioural symptoms including inattentiveness, hyperactivity and impulsiveness. Medicines used to treat ADHD have lots of side-effects and are only used …

Reviews

January 2017

SUMMARY – Emerging technologies for the diagnosis, treatment and management of epilepsy

The NIHR Horizon Scanning Research and Intelligence Centre has published a horizon scanning review of new technologies that are being developed for the diagnosis, treatment and management of epilepsy. Epilepsy is a common neurological condition that affects around 600,000 people in the UK (equivalent to almost 1 in 100 people). It causes sudden and unprovoked …

Reviews

January 2017

REVIEW – Emerging technologies for the diagnosis, treatment and management of epilepsy

The NIHR Horizon Scanning Research and Intelligence Centre has published a horizon scanning review of new technologies that are being developed for the diagnosis, treatment and management of epilepsy. Epilepsy is a common neurological condition that affects around 600,000 people in the UK (equivalent to almost 1 in 100 people). It causes sudden and unprovoked …

Drugs

September 2016

Diazoxide choline controlled-release for Prader-Willi syndrome – first line

Diazoxide choline is a new drug to treat Prader-Willi syndrome. Prader-Willi syndrome is a rare genetic disorder that causes people to eat uncontrollably and become obese. It may also cause learning difficulties and behavioural problems. Diazoxide choline is a slow release tablet that is taken by mouth. Some studies have suggested that diazoxide choline may …

Drugs

August 2016

Nilvadipine for mild to moderate Alzheimer’s disease – first or second line

Alzheimer’s disease is a disease that affects the brain, causing dementia. It is a progressive disease, which means that gradually more of the brain is damaged, so that over time more symptoms develop and symptoms also become more severe. Symptoms include memory loss, communication problems, confusion, problems with reasoning and problems recognising people and places. …

Drugs

August 2016

Nilvadipine for mild to moderate Alzheimer’s disease – first or second line

Alzheimer’s disease is a disease that affects the brain, causing dementia. It is a progressive disease, which means that gradually more of the brain is damaged, so that over time more symptoms develop and symptoms also become more severe. Symptoms include memory loss, communication problems, confusion, problems with reasoning and problems recognising people and places. …

Drugs

August 2016

Nilvadipine for mild to moderate Alzheimer’s disease – first or second line

Alzheimer’s disease is a disease that affects the brain, causing dementia. It is a progressive disease, which means that gradually more of the brain is damaged, so that over time more symptoms develop and symptoms also become more severe. Symptoms include memory loss, communication problems, confusion, problems with reasoning and problems recognising people and places. …

Drugs

August 2016

Cariprazine (Vraylar) for schizophrenia in adults

Schizophrenia is a long term mental health condition that causes changes in the perception of reality. The disease can be distressing and interrupt normal social interaction, with symptoms including hallucinations, confusion, lack of motivation and blunt emotions. Cariprazine is a new drug taken to treat the symptoms of schizophrenia. Cariprazine works by changing the body’s …

Get Alerts